Dr. Christian S. Hinrichs discusses the future of specialized cell therapies, predicting broader access for community clinics similar to CAR T cell treatments.

GLP-1 RAs are associated with a 62% reduction in 5-year mortality in colon cancer patients, especially those with high obesity. The study's findings remained significant after adjusting for ...

A significant communication gap exists between NMIBC patients and providers, with only 18% having regular discussions about ...

Zipalertinib's NDA submission is based on promising efficacy data from the REZILIENT1 trial, showing a 35.2% ORR and ...

Systemic immunotherapy is emerging as a bladder-sparing option for NMIBC, especially for patients unresponsive to BCG therapy ...

The FDA approved enfortumab vedotin and pembrolizumab for MIBC, following a priority review of their sBLA for neoadjuvant and ...

In this discussion, experts review findings from a large real-world dataset comparing clinical outcomes of 2 frontline ...

Osvyrti and Jubereq are FDA-approved denosumab biosimilars for osteoporosis and cancer-related skeletal events, ...

The process of TIL therapy is complex and requires the coordination of multiple specialties at authorized treatment centers, ...

Zidesamtinib targets ROS1+ NSCLC patients with prior TKI treatment, addressing CNS-penetrant treatment challenges and ...

The FDA has granted full approval to tarlatamab-dlle (Imdelltra) for the treatment of adult patients with extensive stage ...

The second study presented at the SITC meeting focuses on a “next-generation” approach following TIL therapy, utilizing ...